Volume | 19,353 |
|
|||||
News | - | ||||||
Day High | 15.14 | Low High |
|||||
Day Low | 14.895 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Alpine Income Property Trust Inc | PINE | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
15.03 | 14.895 | 15.14 | 14.95 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
229 | 19,353 | US$ 15.02 | US$ 290,675 | - | 14.25 - 17.76 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
12:22:07 | 20 | US$ 14.90 | USD |
Alpine Income Property Trust Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
203.05M | 13.62M | - | 45.64M | 2.92M | 0.21 | 69.61 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alpine Income Property News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PINE Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 14.58 | 15.47 | 14.58 | 15.14 | 63,003 | 0.335 | 2.30% |
1 Month | 15.35 | 15.56 | 14.325 | 15.12 | 57,612 | -0.435 | -2.83% |
3 Months | 15.60 | 16.13 | 14.325 | 15.39 | 55,724 | -0.685 | -4.39% |
6 Months | 14.52 | 17.6799 | 14.32 | 15.88 | 57,070 | 0.395 | 2.72% |
1 Year | 15.70 | 17.76 | 14.25 | 16.01 | 71,052 | -0.785 | -5.00% |
3 Years | 18.27 | 21.069 | 14.25 | 17.69 | 73,139 | -3.36 | -18.36% |
5 Years | 19.00 | 21.069 | 7.56 | 17.11 | 69,748 | -4.09 | -21.50% |
Alpine Income Property Description
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing innovative, protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. The company's proprietary scientific platform uses a process known as directed evolution to create therapeutics capable of modulating human immune system proteins. Its product pipeline includes ALPN-101 and ALPN-202. |